US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Drug targeting to myofibroblasts: Implications for fibrosis and

Antifibrotic Agents for Liver Disease - ScienceDirect

CD63 Antibody (MX-49.129.5) SCBT - Santa Cruz Biotechnology

In vivo production of CAR-T cells using CD5/LNP-FAPCAR

Frontiers In vitro Assays and Imaging Methods for Drug Discovery

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Targeting activated hepatic stellate cells (aHSCs) for liver

Anti-CD95/FAS (phospho-Y291) Antibody (A29570)

Targeting fibrosis: mechanisms and clinical trials

Targeting the tumor stroma with an oncolytic adenovirus secreting

CD5L Deficiency Protects Mice Against Bleomycin-Induced Pulmonary

CAR T-mRNA Therapy For Cardiac Fibrosis: A New Way Forward

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis

News: Gene-Editing Clinical Trial Update - CRISPR Medicine